These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Additional use of Aβ₄₂/Aβ₄₀ ratio with cerebrospinal fluid biomarkers P-tau and Aβ₄₂ increases the level of evidence of Alzheimer's disease pathophysiological process in routine practice. Sauvée M; DidierLaurent G; Latarche C; Escanyé MC; Olivier JL; Malaplate-Armand C J Alzheimers Dis; 2014; 41(2):377-86. PubMed ID: 24614902 [TBL] [Abstract][Full Text] [Related]
4. Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease. Kang JH; Vanderstichele H; Trojanowski JQ; Shaw LM Methods; 2012 Apr; 56(4):484-93. PubMed ID: 22503777 [TBL] [Abstract][Full Text] [Related]
5. The added value of Aβ42/Aβ40 in the CSF signature for routine diagnostics of Alzheimer's disease. Biscetti L; Salvadori N; Farotti L; Cataldi S; Eusebi P; Paciotti S; Parnetti L Clin Chim Acta; 2019 Jul; 494():71-73. PubMed ID: 30844364 [TBL] [Abstract][Full Text] [Related]
6. CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. Olsson B; Lautner R; Andreasson U; Öhrfelt A; Portelius E; Bjerke M; Hölttä M; Rosén C; Olsson C; Strobel G; Wu E; Dakin K; Petzold M; Blennow K; Zetterberg H Lancet Neurol; 2016 Jun; 15(7):673-684. PubMed ID: 27068280 [TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of the use of biomarkers in cerebrospinal fluid for Alzheimer's disease. Valcárcel-Nazco C; Perestelo-Pérez L; Molinuevo JL; Mar J; Castilla I; Serrano-Aguilar P J Alzheimers Dis; 2014; 42(3):777-88. PubMed ID: 24916543 [TBL] [Abstract][Full Text] [Related]
8. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort. Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385 [TBL] [Abstract][Full Text] [Related]
9. Analysis of Cerebrospinal Fluid and [11C]PIB PET Biomarkers for Alzheimer's Disease with Updated Protocols. Wang MJ; Yi S; Han JY; Park SY; Jang JW; Chun IK; Giau VV; Bagyinszky E; Lim KT; Kang SM; An SS; Park YH; Youn YC; Kim S J Alzheimers Dis; 2016 May; 52(4):1403-13. PubMed ID: 27163824 [TBL] [Abstract][Full Text] [Related]
10. Clinical validity of cerebrospinal fluid Aβ42, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. Mattsson N; Lönneborg A; Boccardi M; Blennow K; Hansson O; Neurobiol Aging; 2017 Apr; 52():196-213. PubMed ID: 28317649 [TBL] [Abstract][Full Text] [Related]
11. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease. Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O; JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367 [TBL] [Abstract][Full Text] [Related]
14. Cerebrospinal Fluid Biomarkers for the Differential Diagnosis between Alzheimer's Disease and Frontotemporal Lobar Degeneration: Systematic Review, HSROC Analysis, and Confounding Factors. Rivero-Santana A; Ferreira D; Perestelo-Pérez L; Westman E; Wahlund LO; Sarría A; Serrano-Aguilar P J Alzheimers Dis; 2017; 55(2):625-644. PubMed ID: 27716663 [TBL] [Abstract][Full Text] [Related]
15. Cerebrospinal Fluid Biomarkers for Target Engagement and Efficacy in Clinical Trials for Alzheimer's and Parkinson's Diseases. Parnetti L; Eusebi P; Lleó A Front Neurol Neurosci; 2016; 39():117-23. PubMed ID: 27463974 [TBL] [Abstract][Full Text] [Related]
16. Cerebrospinal Fluid Biomarkers for Early and Differential Alzheimer's Disease Diagnosis. Bjerke M; Engelborghs S J Alzheimers Dis; 2018; 62(3):1199-1209. PubMed ID: 29562530 [TBL] [Abstract][Full Text] [Related]
17. Linking CSF and cognition in Alzheimer's disease: Reanalysis of clinical data. Guhra M; Thomas C; Boedeker S; Kreisel S; Driessen M; Beblo T; Ohrmann P; Toepper M Exp Gerontol; 2016 Jan; 73():107-13. PubMed ID: 26585048 [TBL] [Abstract][Full Text] [Related]
18. Alzheimer's Disease-Associated Cerebrospinal Fluid (CSF) Biomarkers do not Correlate with CSF Volumes or CSF Production Rate. Edsbagge M; Andreasson U; Ambarki K; Wikkelsø C; Eklund A; Blennow K; Zetterberg H; Tullberg M J Alzheimers Dis; 2017; 58(3):821-828. PubMed ID: 28505972 [TBL] [Abstract][Full Text] [Related]
19. Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies. Bousiges O; Cretin B; Lavaux T; Philippi N; Jung B; Hezard S; Heitz C; Demuynck C; Gabel A; Martin-Hunyadi C; Blanc F J Alzheimers Dis; 2016; 51(4):1069-83. PubMed ID: 26923009 [TBL] [Abstract][Full Text] [Related]